Aetna Revises Reimbursement Policy For Anemia Medications After CMS Decision
Aetna this month revised the reimbursement policy for several anemia medications — Aranesp and Epogen, marketed by Amgen, and Procrit, marketed by Johnson & Johnson — after CMS recently announced a decision that will limit Medicare coverage for the medications, the Los Angeles Times reports.
[...] unknown wrote an engrossing place today onHere’s a hurried excerptAetna this period revised the reimbursement contract for individual anaemia medications — Aranesp and Epogen, marketed by Amgen, and Procrit, marketed by President & President — after CMS fresh declared a selection that module bounds Medicare … [...]